ReviewThe international journal of cardiovascular imaging2026
Molecular imaging of atherosclerotic plaque vulnerability: a narrative review.
Review in The international journal of cardiovascular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic plaque rupture or erosion underlies most acute coronary and cerebrovascular events. Risk stratification currently relies on luminal stenosis, which poorly predicts thrombotic risk because many events arise from biologically vulnerable plaques with only mild-to-moderate narrowing. Molecular imaging enables non-invasive assessment of the biological processes that drive plaque instability. A structured narrative review of experimental and clinical studies published between 2000 and 2024 was conducted using PubMed and Ovid Embase. Searches related to atherosclerosis, vulnerable plaque, molecular imaging, inflammation, microcalcification, matrix remodelling, angiogenesis, and carotid or coronary disease identified 2,627 records, of which 38 studies were included after screening. Imaging of inflammation and microcalcification shows the greatest clinical maturity, primarily using positron emission tomography (PET). Inflammation is assessed with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG), reflecting macrophage metabolic activity, while active microcalcification is detected with ¹⁸F-sodium fluoride (¹⁸F-NaF), which binds to hydroxyapatite in early calcific deposits. Imaging of fibrous cap degeneration and angiogenesis remains less clinically mature with limited human validation, including matrix metalloproteinase-targeted single-photon emission computed tomography (SPECT) and integrin-targeted magnetic resonance imaging (MRI) approaches. Translation is limited by technical complexity, cost, and scarce outcome-based validation. Molecular imaging provides biologically informed assessment of plaque vulnerability beyond stenosis alone. Imaging of inflammation and microcalcification currently show the greatest potential for risk stratification, although further validation and multimodal integration are required before routine clinical use.
Indexed as
Identifiers
42133271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.